The Electrospinning Company

The Electrospinning Company specializes in the design, development, and manufacturing of nanofibrous biomaterials for implantable medical devices. The company operates on a contract development and manufacturing model, supporting clients from early-stage concepts through to regulated production. It provides end-to-end services, including feasibility, development, and manufacturing under ISO 13485 guidelines, ensuring materials are ready for regulatory submissions worldwide. The firm's proprietary electrospinning technology creates synthetic polymer-based scaffolds and membranes that mimic the body's natural extracellular matrix, which can be used for tissue repair and regeneration.

Founded in 2010 as a spin-out from the UK Science and Technology Facilities Council (STFC), the company initially focused on materials for drug discovery. In 2015, the business pivoted to developing components for medical devices. Ann Kramer joined as CEO in 2012 and has guided the company through significant growth. A key milestone was achieved in 2016 when the company began supplying biomaterial for an FDA-approved medical device in the US. The company is headquartered at the Harwell Science and Innovation Campus in Oxfordshire, UK, where it operates a purpose-built cleanroom facility. In 2021, a major £4.5 million investment round was led by strategic partner Confluent Medical Technologies, a US-based materials science company.

The Electrospinning Company serves the medical device and regenerative medicine markets. Its technology platform produces resorbable and non-resorbable materials used in various therapeutic areas, including corneal repair, ligament wraps, vascular surgery, wound healing, and ophthalmology. The company has developed its own technology platforms, such as Symatix®, a synthetic membrane alternative, and Kalyptix®, a protective membrane for cell therapy. Revenue is generated through contract services for development and manufacturing, as well as through the potential out-licensing of its proprietary technologies.

Keywords: electrospinning, biomaterials, medical devices, regenerative medicine, nanofiber, tissue engineering, implantable devices, contract manufacturing, ISO 13485, synthetic scaffolds, drug delivery, cell therapy, resorbable materials, wound care, ophthalmology, vascular grafts, medical technology, life sciences, nanotechnology, advanced materials, FDA-approved components